Quest Diagnostics Incorporated
NYSE:DGXMedical - Diagnostics & Research
-$3.41 today
- Market cap
- $28.57B
- Beta
- 0.59
- P/E (TTM)
- 20.9
- EPS (TTM)
- $9.31
- Dividend yield
- 1.68%
Volume 1.30M
Average 0.91M
DGX Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Quest Diagnostics IncorporatedNYSE: DGX
Accounts Payables · Q3 FY2026 · quarter ended Sep 2026
Accounts payables dips below year-ago levels
Q3 FY2026 accounts payables of $114M fell 8.1% year over year, behind the +130.1% change in trailing-twelve-month accounts payables. Sequentially, it fell 19.7% from the prior quarter.
Context
- Accounts payables amounted to 1.2% of revenue in FY2025, up 0.5 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -8.1% toward the trailing-twelve-month pace of +130.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 129M USD
- Year-over-year change
- +292.5%
- 4-year CAGR
- +38.6%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 129M | +292.5% |
| FY2024 | 2024-12-31 | (67M) | -21.8% |
| FY2023 | 2023-12-31 | (55M) | +63.1% |
| FY2022 | 2022-12-31 | (149M) | -525.7% |
| FY2021 | 2021-12-31 | 35M | — |
Accounts Payables vs competitors
How DGX compares with its peers on the latest reported figures
- DGX's LTM Sep 2026 accounts payables of $260M is the largest of the 9 companies compared; the peer median is $15.89M.
- Its year-over-year change of +130.1% is the 4th highest of 8, against a peer median of -54.1%.
- Accounts payables amounts to 2.2% of revenue for DGX, versus a peer median of 1.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $260M | +130.1% | — | 2.2% | |
| LTM Jun 2026 | $122.6M | -383.8% | — | 0.9% | |
| LTM Sep 2026 | $80.38M | +664.5% | +1.7% | 3.4% | |
| LTM Sep 2026 | $41.71M | — | — | 3.3% | |
| LTM Jun 2026 | $29.39M | +734.8% | -48.3% | 1.1% | |
| LTM Jun 2026 | $28M | -54.1% | — | 0.6% | |
| LTM Jul 2026 | $14M | -6266.1% | — | 0.5% | |
| LTM Jun 2026 | $3.79M | +138.2% | — | 2.3% | |
| LTM Jun 2026 | $1.56M | -130.5% | +68.6% | 0.1% | |
| Peer median (excluding DGX) | $15.89M | -54.1% | +1.7% | 1.0% | |
Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.08B | 1.02B | 908M | 921M | 1.05B |
| Depreciation & Amortization | 408M | 437M | 439M | 493M | 570M |
| Deferred Income Tax | (57M) | 1M | (49M) | 13M | 105M |
| Stock-Based Compensation | 79M | 77M | 77M | 88M | 88M |
| Change in Working Capital | 87M | 119M | (145M) | (201M) | 50M |
| Accounts Receivables | 81M | 246M | (15M) | (71M) | (106M) |
| Inventory | (20M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 35M | (149M) | (55M) | (67M) | 129M |
| Other Working Capital | (9M) | 22M | (75M) | (63M) | 27M |
| Other Non-Cash Items | (364M) | 69M | 42M | 20M | 27M |
| Operating Cash Flow | 2.23B | 1.72B | 1.27B | 1.33B | 1.89B |
| Capital Expenditures | (403M) | (404M) | (408M) | (425M) | (527M) |
| Acquisitions (Net) | 424M | (144M) | (611M) | (2.16B) | (101M) |
| Purchases of Investments | (3M) | (5M) | 0 | 0 | 0 |
| Sales of Investments | 403M | 5M | 0 | 0 | 0 |
| Other Investing Activities | (400M) | 5M | (42M) | 41M | (3M) |
| Investing Cash Flow | 21M | (543M) | (1.06B) | (2.55B) | (631M) |
| Debt Repayment | (2M) | (2M) | 748M | 1.54B | (602M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 79M |
| Common Stock Repurchased | (2.2B) | (1.41B) | (275M) | (151M) | (450M) |
| Dividends Paid | (309M) | (305M) | (314M) | (331M) | (353M) |
| Other Financing Activities | (30M) | (17M) | 1M | 23M | (62M) |
| Financing Cash Flow | (2.54B) | (1.73B) | 160M | 1.08B | (1.39B) |
| Effect of Forex Changes | 0 | 0 | 0 | (7M) | 4M |
| Net Change in Cash | (286M) | (557M) | 371M | (137M) | (129M) |
| Free Cash Flow | 1.83B | 1.31B | 864M | 909M | 1.36B |
Quest Diagnostics Incorporated
NYSE:DGX
Intrinsic Alpha fair value
Locked
Current Price
$259.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.